John Newman
Stock Analyst at Canaccord Genuity
(2.16)
# 2,774
Out of 4,749 analysts
81
Total ratings
46.38%
Success rate
-7.24%
Average return
Main Sectors:
Stocks Rated by John Newman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATRA Atara Biotherapeutics | Maintains: Buy | $21 → $17 | $8.88 | +91.44% | 4 | Jan 17, 2025 | |
| REGN Regeneron Pharmaceuticals | Initiates: Hold | $165 | $672.98 | -75.48% | 16 | Dec 17, 2024 | |
| BNTX BioNTech SE | Maintains: Buy | $171 | $123.77 | +38.16% | 7 | Nov 18, 2024 | |
| MCRB Seres Therapeutics | Maintains: Buy | $10 | $0.84 | +1,083.57% | 9 | Nov 14, 2024 | |
| DCTH Delcath Systems | Maintains: Buy | $21 | $15.60 | +34.62% | 1 | Oct 18, 2024 | |
| ACLX Arcellx | Maintains: Buy | $85 → $115 | $68.13 | +68.79% | 8 | Oct 17, 2024 | |
| ACET Adicet Bio | Maintains: Buy | $19 → $8 | $0.89 | +803.95% | 6 | Sep 11, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $35 → $14 | $1.80 | +677.78% | 2 | Aug 8, 2024 | |
| MRUS Merus | Maintains: Buy | $67 | $40.94 | +63.65% | 2 | Jul 25, 2024 | |
| RNAC Cartesian Therapeutics | Maintains: Buy | $38 → $43 | $19.31 | +122.68% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $6 | $0.18 | +3,309.09% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $2.66 | +313.53% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.73 | +585.87% | 2 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $44 | $34.39 | +27.94% | 9 | Feb 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,720 → $400 | $7.75 | +5,061.29% | 4 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $220 | $7.25 | +2,934.48% | 3 | Jun 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $38 | $13.52 | +181.07% | 2 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $27 | $5.24 | +415.27% | 2 | Sep 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Speculative Buy | n/a | $7.95 | - | 1 | Sep 13, 2017 |
Atara Biotherapeutics
Jan 17, 2025
Maintains: Buy
Price Target: $21 → $17
Current: $8.88
Upside: +91.44%
Regeneron Pharmaceuticals
Dec 17, 2024
Initiates: Hold
Price Target: $165
Current: $672.98
Upside: -75.48%
BioNTech SE
Nov 18, 2024
Maintains: Buy
Price Target: $171
Current: $123.77
Upside: +38.16%
Seres Therapeutics
Nov 14, 2024
Maintains: Buy
Price Target: $10
Current: $0.84
Upside: +1,083.57%
Delcath Systems
Oct 18, 2024
Maintains: Buy
Price Target: $21
Current: $15.60
Upside: +34.62%
Arcellx
Oct 17, 2024
Maintains: Buy
Price Target: $85 → $115
Current: $68.13
Upside: +68.79%
Adicet Bio
Sep 11, 2024
Maintains: Buy
Price Target: $19 → $8
Current: $0.89
Upside: +803.95%
Allogene Therapeutics
Aug 8, 2024
Maintains: Buy
Price Target: $35 → $14
Current: $1.80
Upside: +677.78%
Merus
Jul 25, 2024
Maintains: Buy
Price Target: $67
Current: $40.94
Upside: +63.65%
Cartesian Therapeutics
Jul 3, 2024
Maintains: Buy
Price Target: $38 → $43
Current: $19.31
Upside: +122.68%
May 16, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $0.18
Upside: +3,309.09%
May 9, 2024
Maintains: Buy
Price Target: $12 → $11
Current: $2.66
Upside: +313.53%
Jun 23, 2023
Reiterates: Buy
Price Target: $5
Current: $0.73
Upside: +585.87%
Feb 16, 2022
Maintains: Buy
Price Target: $52 → $44
Current: $34.39
Upside: +27.94%
Aug 10, 2021
Downgrades: Hold
Price Target: $1,720 → $400
Current: $7.75
Upside: +5,061.29%
Jun 13, 2018
Maintains: Buy
Price Target: $210 → $220
Current: $7.25
Upside: +2,934.48%
Oct 17, 2017
Maintains: Buy
Price Target: $30 → $38
Current: $13.52
Upside: +181.07%
Sep 13, 2017
Maintains: Buy
Price Target: $12 → $27
Current: $5.24
Upside: +415.27%
Sep 13, 2017
Downgrades: Speculative Buy
Price Target: n/a
Current: $7.95
Upside: -